Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... work by a Florida State University research team has ... your temperature, emit white light, and convert photon energy ... like a butterfly. , Biwu Ma, associate professor in ... FAMU-FSU College of Engineering, created the molecule in a ... discover that his creation has many other unique capabilities. ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
Breaking Biology Technology:New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2PrimeSource Chooses SoundConnect as Collaboration Provider 2
... accurately while minimizing ... 6 During his annual,physical check-up in March, David Kelver,s ... the right one looked a bit swollen. The,doctor concluded, however, ... own, and sent him home. Several months later, Kelver, a ...
... showing that Microsoft SQL Server ... 1 petabyte., REDMOND, Wash., Nov. 6 ... management and business,intelligence platform, Microsoft SQL Server 2008, ... scale new heights in data warehousing,and transaction processing., ...
... at Rodman & Renshaw,10th Annual Healthcare Conference" issued on ... over PR Newswire, we are advised by a,representative of ... the first paragraph. Complete, corrected release follows:, , ... the development of microRNA-based diagnostics, announced today it,will present ...
Cached Biology Technology:Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 2Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 3Cancer Care of Western New York Becomes First Center in Western New York to Treat Cancer with RapidArc(TM) Radiotherapy Technology from Varian Medical Systems 4Could Database Software Help Cure Alzheimer's and Save the Earth? 2Could Database Software Help Cure Alzheimer's and Save the Earth? 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 2/C O R R E C T I O N -- Rosetta Genomics Ltd/ 3/C O R R E C T I O N -- Rosetta Genomics Ltd/ 4/C O R R E C T I O N -- Rosetta Genomics Ltd/ 5/C O R R E C T I O N -- Rosetta Genomics Ltd/ 6
(Date:9/1/2014)... a life without light. They emit echolocation sounds and use ... obstacles or prey. In their brains, they have a spatial ... researchers at Technische Universitt Mnchen (TUM) has shown for the ... , Closer objects appear larger , ... the number of activated neurons in its brain increases. As ...
(Date:8/31/2014)... highly infectious bacteria C. diff , that causes ... a team at the University of Leicester. , Using ... it is possible to identify the unique ,smell, of ... diagnosis of the condition., What is more, the Leicester ... strains of the disease simply from their smell ...
(Date:8/31/2014)... in Nature Climate Change , suggests that if ... not exceed, the global targets for total greenhouse gas (GHG) ... should all think carefully about the food we choose and ... world is just one of a number of actions that ... ensure there is enough food for all. , As ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... clear change in salinity has been detected in the ... global rainfall and evaporation cycle., In a paper published ... the Commonwealth Scientific and Industrial Research Organisation (CSIRO) and ... of salinity in the global ocean during the past ...
... scientists has found there has been a massive reduction in ... of Antarctica.,Comparing detailed measurements taken during the Australian Antarctic program,s ... back to 1970, scientists estimate there has been as much ... Antarctic Bottom Water, the cold dense water that drives global ...
... Berlin, Germany, May 21, 2012 IMPACT World+, ... methodology was launched today in Berlin, Germany during the ... Meeting. The event featured the results of this innovative ... experts and researchers from five countries., The production and ...
Cached Biology News:Earth's water cycle intensifying with atmospheric warming 2Latest Southern Ocean research shows continuing deep ocean change 2Latest Southern Ocean research shows continuing deep ocean change 3Launch of IMPACT World+ 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
Biology Products: